NCT04910061

Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

A Single-centre Trial to Investigate the Safety and Pharmacokinetics of Orally Administered Nicotinamide Mononucleotide (NMN, 400mg) Over 29 Days of Supplementation in Healthy Adults.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Seneque SA · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety, pharmacokinetic profile, and effects of nicotinamide mononucleotide (NMN-C) in healthy adults, 18-65 years of age. The effects will be studied over the course of 30 days in a repeated-dose study through the collection of blood and urine samples, and administration of surveys and questionnaires.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nicotinamide mononucleotide (NMN-C)	Daily supplementation with NMN-C at 400 mg for 29 days in total

Timeline

• Start date: 2021-08-05
• Primary completion: 2022-09-01
• Completion: 2023-03-01
• First posted: 2021-06-02
• Last updated: 2023-03-30

Locations

1 site across 1 country: Canada